 Innovation and firm size in the pharmaceutical industryRoxana Bobulescu and Celine Soulas International Journal of Business Environment, 2006, vol. 1, issue 2, 253-264 Abstract: The paper explains the main features of the relationship between firm size and innovativeness in the pharmaceutical industry. As the biotechnological paradigm is progressively replacing the chemical one, the biotech start-ups are the principal engine of R&D activity. They discover new molecules and impulse drug innovation. Still, big pharmaceutical companies (big pharmas) have some advantages, such as benefiting from higher funds to support development of new drugs, scale and scope economies in R&D. Partnerships between small and big firms are developed on a win-win basis. Consequently, the size of the firm is a moving target. Innovation is to be linked with industrial, technological networks. Small firms are cooperating and so increasing returns to scale may appear at the level of the research networks, strategic alliances or bio-clusters. Industrial policies stimulating innovation as a competitive edge should then concentrate on creating strong incentives for small firms to cooperate. Keywords: bioclusters; biotechnology; industrial policy; SMEs; innovation; firm size; pharmaceutical industry; large firms; strategic alliances; biotech start-ups; R&D; research and development; industrial networks; technological networks; research networks; small firms; cooperation. (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:ids:ijbenv:v:1:y:2006:i:2:p:253-264 Access Statistics for this article More articles in International Journal of Business Environment from Inderscience Enterprises Ltd |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.